Vecta I Ltd.

The Artemis Catastrophe Bond and Insurance-linked Securities Deal Directory aims to provide a one-stop resource for information on every cat bond and ILS transaction we hold information on. The content of this Deal Directory is provided as is and there will be some omissions. Help us to keep these cat bond and ILS transaction summaries up to date by contacting us if you see an error or omission that you can correct.

Vecta I Ltd. - At a glance:

• Issuer / SPV: Vecta I Ltd.
• Cedent / Sponsor: Aurigen Reinsurance
• Placement / structuring agent/s: Credit Agricole Securities structured the deal and acted as joint-bookrunner alongside Swiss Re Capital Markets
• Risk modelling / calculation agents etc: Oliver Wyman
• Risks / Perils covered: Embedded value securitization of life insurance mortality and lapse risk
• Size: C$120m
• Trigger type: NA
• Ratings: S&P: 'BBB+'
• Date of issue: Dec 2011
• Artemis.bm news coverage: Articles discussing Vecta I Ltd. from Artemis.bm

Vecta I Ltd. - Full details

This deal see’s Aurigen Reinsurance Ltd. (ARL) entering into a retrocession agreement with Vecta I Ltd., a newly formed Bermuda domiciled SPV, after which ARL will retrocede the life business to Vecta for which Vecta pays a ceding commission. ARL has also entered into a reinsurance agreement with Aurigen Reinsurance Company and the Vecta notes will cover Vecta’s obligations to ARL under the retrocession agreement.

This is the first 144A embedded value life insurance securitization deal to be issued since 2007. It’s also the first ever Canadian life insurance securitization transaction. The Vecta I Ltd. transaction enables Aurigen Reinsurance to monetise the cash flows associated with life insurance and mortality business it has reinsured.

The transaction covers life policies which Aurigen Reinsurance acquired through 12 reinsurance treaty transactions with six separate life insurance companies. The life business covered in this securitization includes some 447,444 term, permanent, and universal life (UL) policies on Canadian lives with an aggregate face value of approximately C$22 billion in 2010.

The transaction includes a single tranche of notes rated BBB+ (sf) by Standard and Poor’s. The notes have an expected maturity of 6.25 years and a coupon rate of 8.0%.